Solabegron: a potential future addition to the beta-3 adrenoceptor agonist armamentarium for the management of overactive bladder

摘要

Introduction: Overactive bladder (OAB) affects many women and men worldwide and has a significant adverse effect on a person's quality of life. Historically, behavioral therapy and anti-muscarinic agents have been the primary therapies used in the management of OAB. However, persistence with anti-muscarinic therapy has been limited. The role of beta-3 agonists is established in the management of OAB with the first beta-3 agonist recently approved by the FDA. Solabegron is one such selective beta-3 agonist currently under investigation.